| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urethral Obstruction | 8 | 2023 | 56 | 1.570 |
Why?
|
| Kidney Diseases | 9 | 2020 | 691 | 1.510 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 4 | 2011 | 23 | 1.130 |
Why?
|
| Fetal Diseases | 9 | 2023 | 388 | 1.120 |
Why?
|
| Glomerulonephritis | 6 | 2019 | 109 | 1.080 |
Why?
|
| Urinary Bladder Neck Obstruction | 4 | 2018 | 35 | 0.990 |
Why?
|
| Kidney | 16 | 2022 | 2146 | 0.970 |
Why?
|
| Kidney Failure, Chronic | 6 | 2023 | 960 | 0.960 |
Why?
|
| Hypertension | 11 | 2021 | 1503 | 0.880 |
Why?
|
| Receptors, Complement | 4 | 2009 | 48 | 0.800 |
Why?
|
| Interleukin-12 | 6 | 2009 | 253 | 0.800 |
Why?
|
| Nephrology | 1 | 2023 | 151 | 0.780 |
Why?
|
| Kidney Transplantation | 4 | 2011 | 755 | 0.730 |
Why?
|
| Urinary Tract | 3 | 2020 | 82 | 0.730 |
Why?
|
| Hypertension, Renal | 3 | 2018 | 30 | 0.670 |
Why?
|
| Lupus Nephritis | 2 | 2009 | 48 | 0.650 |
Why?
|
| Renal Insufficiency | 3 | 2017 | 321 | 0.650 |
Why?
|
| Denys-Drash Syndrome | 1 | 2017 | 7 | 0.620 |
Why?
|
| Receptors, Immunologic | 2 | 2014 | 309 | 0.620 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2017 | 69 | 0.590 |
Why?
|
| WT1 Proteins | 1 | 2017 | 106 | 0.580 |
Why?
|
| Mice, Inbred MRL lpr | 4 | 2009 | 23 | 0.570 |
Why?
|
| Urogenital Abnormalities | 2 | 2016 | 174 | 0.570 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2021 | 787 | 0.560 |
Why?
|
| Chromosome Mapping | 5 | 2018 | 1471 | 0.540 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2015 | 43 | 0.530 |
Why?
|
| Rats, Inbred SHR | 10 | 2020 | 113 | 0.520 |
Why?
|
| Proteome | 2 | 2009 | 561 | 0.480 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2020 | 5539 | 0.470 |
Why?
|
| Graft Survival | 3 | 2011 | 1062 | 0.430 |
Why?
|
| Nephritis, Hereditary | 2 | 2022 | 47 | 0.420 |
Why?
|
| Receptor, Anaphylatoxin C5a | 4 | 2007 | 13 | 0.410 |
Why?
|
| Renal Replacement Therapy | 3 | 2018 | 135 | 0.400 |
Why?
|
| Proteomics | 2 | 2009 | 1380 | 0.370 |
Why?
|
| Genetic Variation | 3 | 2020 | 2086 | 0.370 |
Why?
|
| Hemodiafiltration | 2 | 2021 | 18 | 0.360 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2009 | 40 | 0.360 |
Why?
|
| Stroke | 5 | 2020 | 1144 | 0.350 |
Why?
|
| Ultrasonography, Prenatal | 7 | 2023 | 830 | 0.350 |
Why?
|
| Kidney Tubules | 2 | 2013 | 137 | 0.350 |
Why?
|
| Monocytes | 4 | 2001 | 788 | 0.340 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2008 | 10 | 0.340 |
Why?
|
| Complement C3a | 2 | 2007 | 18 | 0.330 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2020 | 1033 | 0.330 |
Why?
|
| Albuminuria | 3 | 2014 | 113 | 0.330 |
Why?
|
| Sulfhydryl Compounds | 1 | 2008 | 72 | 0.330 |
Why?
|
| Proteinuria | 2 | 2006 | 155 | 0.320 |
Why?
|
| Fetus | 3 | 2023 | 601 | 0.320 |
Why?
|
| Kidney Glomerulus | 4 | 2013 | 156 | 0.320 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2008 | 157 | 0.320 |
Why?
|
| Renal Dialysis | 4 | 2023 | 945 | 0.320 |
Why?
|
| Urologic Diseases | 2 | 2019 | 78 | 0.310 |
Why?
|
| Prenatal Care | 2 | 2023 | 325 | 0.300 |
Why?
|
| Complement C4 | 1 | 2007 | 15 | 0.300 |
Why?
|
| Complement Factor H | 2 | 2008 | 33 | 0.300 |
Why?
|
| Plasma Exchange | 2 | 2018 | 117 | 0.290 |
Why?
|
| Histocompatibility Antigens | 1 | 2007 | 74 | 0.290 |
Why?
|
| Glomerular Filtration Rate | 3 | 2021 | 602 | 0.290 |
Why?
|
| Urinary Bladder | 4 | 2023 | 575 | 0.290 |
Why?
|
| Dendritic Cells | 6 | 2009 | 1085 | 0.290 |
Why?
|
| Haplotypes | 5 | 2019 | 856 | 0.290 |
Why?
|
| Graft Rejection | 1 | 2011 | 834 | 0.280 |
Why?
|
| Kidney Tubules, Proximal | 2 | 2004 | 142 | 0.280 |
Why?
|
| Humans | 67 | 2023 | 261506 | 0.280 |
Why?
|
| Infant | 16 | 2023 | 13310 | 0.270 |
Why?
|
| Glomerulonephritis, IGA | 2 | 2018 | 16 | 0.270 |
Why?
|
| Female | 46 | 2023 | 141928 | 0.270 |
Why?
|
| Mycophenolic Acid | 2 | 2016 | 148 | 0.260 |
Why?
|
| Cholera Toxin | 2 | 2009 | 63 | 0.260 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2019 | 247 | 0.260 |
Why?
|
| Animals, Congenic | 3 | 2020 | 7 | 0.260 |
Why?
|
| Genome-Wide Association Study | 2 | 2014 | 2265 | 0.250 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2007 | 223 | 0.250 |
Why?
|
| Immunosuppressive Agents | 3 | 2014 | 1375 | 0.250 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 4549 | 0.240 |
Why?
|
| Protein Methyltransferases | 1 | 2004 | 45 | 0.240 |
Why?
|
| Pregnancy | 10 | 2023 | 7573 | 0.240 |
Why?
|
| Glomerular Mesangium | 3 | 2003 | 40 | 0.240 |
Why?
|
| Animals | 25 | 2021 | 59536 | 0.230 |
Why?
|
| Mutation | 5 | 2022 | 15179 | 0.230 |
Why?
|
| Retrospective Studies | 21 | 2023 | 37905 | 0.230 |
Why?
|
| Glomerulonephritis, Membranous | 2 | 2018 | 17 | 0.220 |
Why?
|
| Cytomegalovirus Infections | 1 | 2007 | 462 | 0.220 |
Why?
|
| Reperfusion Injury | 1 | 2004 | 145 | 0.220 |
Why?
|
| Rats | 7 | 2020 | 6086 | 0.220 |
Why?
|
| Child | 21 | 2022 | 29154 | 0.220 |
Why?
|
| Creatinine | 2 | 2021 | 531 | 0.210 |
Why?
|
| Endovascular Procedures | 2 | 2019 | 516 | 0.210 |
Why?
|
| Cystoscopy | 3 | 2017 | 88 | 0.210 |
Why?
|
| Signal Transduction | 3 | 2014 | 11965 | 0.210 |
Why?
|
| Hematuria | 1 | 2022 | 85 | 0.210 |
Why?
|
| Disease Progression | 7 | 2018 | 6682 | 0.210 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2001 | 11 | 0.200 |
Why?
|
| Male | 33 | 2022 | 123000 | 0.200 |
Why?
|
| Receptors, Peptide | 1 | 2001 | 86 | 0.200 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2001 | 40 | 0.200 |
Why?
|
| Blood Pressure | 4 | 2016 | 1467 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 3 | 2010 | 4975 | 0.190 |
Why?
|
| Stromal Interaction Molecule 1 | 1 | 2020 | 7 | 0.190 |
Why?
|
| Child, Preschool | 14 | 2021 | 16273 | 0.190 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2000 | 17 | 0.190 |
Why?
|
| ORAI1 Protein | 1 | 2020 | 4 | 0.190 |
Why?
|
| Crosses, Genetic | 2 | 2013 | 241 | 0.180 |
Why?
|
| Perinatal Mortality | 2 | 2019 | 41 | 0.180 |
Why?
|
| Ovarian Neoplasms | 3 | 2010 | 4638 | 0.180 |
Why?
|
| Risk Factors | 8 | 2021 | 17523 | 0.180 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2019 | 61 | 0.180 |
Why?
|
| Autoantibodies | 2 | 2020 | 576 | 0.170 |
Why?
|
| Biomarkers | 2 | 2018 | 5047 | 0.170 |
Why?
|
| Time Factors | 7 | 2017 | 12926 | 0.170 |
Why?
|
| Aneurysm, Ruptured | 1 | 2019 | 45 | 0.170 |
Why?
|
| Foreign-Body Migration | 2 | 2018 | 117 | 0.170 |
Why?
|
| Nephrosis, Lipoid | 1 | 2018 | 12 | 0.170 |
Why?
|
| Receptors, Interleukin | 1 | 1999 | 97 | 0.170 |
Why?
|
| Complement C5a | 3 | 2007 | 36 | 0.170 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2018 | 43 | 0.170 |
Why?
|
| Hypertension, Renovascular | 1 | 2018 | 22 | 0.160 |
Why?
|
| Nervous System Malformations | 1 | 2020 | 133 | 0.160 |
Why?
|
| Extracorporeal Circulation | 1 | 2018 | 43 | 0.160 |
Why?
|
| Cells, Cultured | 7 | 2020 | 5637 | 0.160 |
Why?
|
| Infant, Newborn | 8 | 2020 | 8223 | 0.160 |
Why?
|
| Mice | 13 | 2012 | 34495 | 0.160 |
Why?
|
| Complement C3 | 2 | 2013 | 78 | 0.160 |
Why?
|
| Intracranial Aneurysm | 1 | 2019 | 123 | 0.160 |
Why?
|
| Renal Artery Obstruction | 1 | 2018 | 38 | 0.160 |
Why?
|
| Mice, Knockout | 5 | 2012 | 5710 | 0.160 |
Why?
|
| Chromosomes, Mammalian | 1 | 2018 | 59 | 0.160 |
Why?
|
| Quantitative Trait Loci | 3 | 2018 | 374 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 5 | 2012 | 6942 | 0.160 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2018 | 47 | 0.160 |
Why?
|
| Urologic Surgical Procedures | 1 | 2018 | 93 | 0.160 |
Why?
|
| Receptors, Fc | 1 | 2018 | 69 | 0.160 |
Why?
|
| Nephritis | 1 | 2018 | 36 | 0.160 |
Why?
|
| Mitochondrial Diseases | 1 | 2019 | 137 | 0.160 |
Why?
|
| Ammonia | 1 | 1998 | 88 | 0.150 |
Why?
|
| Gene Expression Profiling | 3 | 2008 | 5159 | 0.150 |
Why?
|
| Transplantation, Homologous | 3 | 2011 | 2843 | 0.150 |
Why?
|
| Germ Cells | 1 | 2019 | 335 | 0.150 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2018 | 59 | 0.150 |
Why?
|
| Citric Acid | 1 | 2017 | 54 | 0.150 |
Why?
|
| Edema | 1 | 2019 | 267 | 0.150 |
Why?
|
| Antigens, CD | 2 | 2000 | 1385 | 0.150 |
Why?
|
| Disease Models, Animal | 7 | 2020 | 7222 | 0.150 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 862 | 0.150 |
Why?
|
| Prednisone | 1 | 1999 | 984 | 0.150 |
Why?
|
| Breast Neoplasms, Male | 1 | 2018 | 229 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 6207 | 0.140 |
Why?
|
| Lymphocytes | 2 | 2014 | 1234 | 0.140 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2019 | 534 | 0.140 |
Why?
|
| Hematocrit | 2 | 2014 | 142 | 0.140 |
Why?
|
| Peritoneal Dialysis | 1 | 2018 | 125 | 0.140 |
Why?
|
| Anesthesia, General | 1 | 2018 | 239 | 0.140 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 1996 | 25 | 0.140 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2019 | 412 | 0.140 |
Why?
|
| Fetal Therapies | 1 | 2017 | 79 | 0.140 |
Why?
|
| Recurrence | 4 | 2019 | 4758 | 0.140 |
Why?
|
| Liver Failure, Acute | 1 | 2017 | 88 | 0.140 |
Why?
|
| Coatomer Protein | 1 | 2016 | 35 | 0.140 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2016 | 81 | 0.140 |
Why?
|
| Nephrotic Syndrome | 1 | 1996 | 57 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 1999 | 629 | 0.140 |
Why?
|
| Atypical Hemolytic Uremic Syndrome | 1 | 2015 | 19 | 0.140 |
Why?
|
| RNA, Messenger | 6 | 2004 | 6150 | 0.130 |
Why?
|
| Catheters, Indwelling | 1 | 2018 | 374 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2001 | 1271 | 0.130 |
Why?
|
| Immunohistochemistry | 5 | 2018 | 7548 | 0.130 |
Why?
|
| Cecal Neoplasms | 1 | 2014 | 7 | 0.130 |
Why?
|
| Forecasting | 1 | 2018 | 694 | 0.130 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 206 | 0.130 |
Why?
|
| Urinary Fistula | 1 | 2015 | 27 | 0.130 |
Why?
|
| Electrocoagulation | 1 | 2015 | 65 | 0.130 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 1688 | 0.130 |
Why?
|
| Prognosis | 8 | 2018 | 21713 | 0.130 |
Why?
|
| Cyclic AMP | 2 | 2009 | 358 | 0.130 |
Why?
|
| Polycystic Kidney, Autosomal Recessive | 1 | 2014 | 9 | 0.130 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2014 | 38 | 0.120 |
Why?
|
| Urethra | 1 | 2015 | 144 | 0.120 |
Why?
|
| Fetoscopy | 1 | 2017 | 304 | 0.120 |
Why?
|
| Gestational Age | 4 | 2020 | 1069 | 0.120 |
Why?
|
| Adolescent | 12 | 2020 | 31252 | 0.120 |
Why?
|
| Drainage | 1 | 2016 | 416 | 0.120 |
Why?
|
| Adult | 16 | 2020 | 77950 | 0.120 |
Why?
|
| Membrane Proteins | 1 | 2004 | 2819 | 0.120 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 238 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2015 | 3251 | 0.120 |
Why?
|
| Lung | 3 | 2015 | 3151 | 0.120 |
Why?
|
| Unnecessary Procedures | 1 | 2014 | 104 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 739 | 0.120 |
Why?
|
| Moving and Lifting Patients | 1 | 2013 | 1 | 0.110 |
Why?
|
| Hospital Mortality | 2 | 2017 | 1274 | 0.110 |
Why?
|
| Treatment Outcome | 11 | 2019 | 32848 | 0.110 |
Why?
|
| Interferon-gamma | 5 | 2012 | 1144 | 0.110 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 500 | 0.110 |
Why?
|
| Lung Diseases | 2 | 2016 | 717 | 0.110 |
Why?
|
| Complement C7 | 1 | 2012 | 2 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 2231 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 4744 | 0.110 |
Why?
|
| Physical Exertion | 1 | 2013 | 113 | 0.110 |
Why?
|
| Liver Transplantation | 2 | 2018 | 1112 | 0.110 |
Why?
|
| Hemoglobins | 1 | 2014 | 477 | 0.110 |
Why?
|
| Immunoglobulin G | 2 | 2019 | 1021 | 0.110 |
Why?
|
| Prenatal Diagnosis | 4 | 2018 | 590 | 0.110 |
Why?
|
| Species Specificity | 3 | 2014 | 777 | 0.110 |
Why?
|
| Taxoids | 3 | 2010 | 967 | 0.100 |
Why?
|
| Cerebral Palsy | 1 | 2013 | 63 | 0.100 |
Why?
|
| Cytokines | 2 | 2000 | 2809 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2017 | 787 | 0.100 |
Why?
|
| Alleles | 2 | 2014 | 2437 | 0.100 |
Why?
|
| CD40 Ligand | 2 | 2002 | 115 | 0.100 |
Why?
|
| Biopsy | 3 | 2022 | 3443 | 0.100 |
Why?
|
| Databases as Topic | 1 | 2011 | 133 | 0.100 |
Why?
|
| Middle Aged | 14 | 2019 | 86204 | 0.100 |
Why?
|
| Virulence Factors, Bordetella | 2 | 2001 | 41 | 0.100 |
Why?
|
| Risk Assessment | 5 | 2019 | 6869 | 0.100 |
Why?
|
| Young Adult | 8 | 2020 | 21445 | 0.100 |
Why?
|
| Epigenomics | 1 | 2012 | 266 | 0.100 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 2045 | 0.090 |
Why?
|
| Laser Therapy | 1 | 2015 | 411 | 0.090 |
Why?
|
| Brain Injuries | 1 | 2016 | 787 | 0.090 |
Why?
|
| Population Groups | 1 | 2010 | 42 | 0.090 |
Why?
|
| Cognitive Dysfunction | 1 | 2015 | 333 | 0.090 |
Why?
|
| Fibrosis | 1 | 2013 | 793 | 0.090 |
Why?
|
| Forkhead Transcription Factors | 2 | 2016 | 778 | 0.090 |
Why?
|
| Granzymes | 1 | 2010 | 91 | 0.090 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 552 | 0.090 |
Why?
|
| Platinum Compounds | 1 | 2010 | 131 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 4892 | 0.090 |
Why?
|
| Quinazolines | 1 | 2014 | 923 | 0.090 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2012 | 247 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1516 | 0.090 |
Why?
|
| Hepcidins | 1 | 2009 | 34 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 1303 | 0.090 |
Why?
|
| Survival Analysis | 4 | 2018 | 9180 | 0.090 |
Why?
|
| Molecular Sequence Data | 3 | 2014 | 6089 | 0.090 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2009 | 62 | 0.090 |
Why?
|
| Drug Administration Schedule | 4 | 2015 | 3472 | 0.090 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 998 | 0.090 |
Why?
|
| Patient Selection | 1 | 2017 | 2055 | 0.090 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 76 | 0.080 |
Why?
|
| Amniotic Fluid | 2 | 2020 | 123 | 0.080 |
Why?
|
| CD8 Antigens | 1 | 2009 | 170 | 0.080 |
Why?
|
| Cognition | 1 | 2015 | 968 | 0.080 |
Why?
|
| Immunoassay | 1 | 2009 | 216 | 0.080 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 1 | 2008 | 4 | 0.080 |
Why?
|
| Chemokine CCL2 | 2 | 2000 | 203 | 0.080 |
Why?
|
| Oligohydramnios | 2 | 2019 | 37 | 0.080 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 1363 | 0.080 |
Why?
|
| Tissue and Organ Procurement | 1 | 2011 | 233 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 1323 | 0.080 |
Why?
|
| Mediastinitis | 1 | 2008 | 22 | 0.080 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 29902 | 0.080 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2012 | 426 | 0.080 |
Why?
|
| Ki-67 Antigen | 1 | 2010 | 666 | 0.080 |
Why?
|
| Calcium Signaling | 2 | 2020 | 284 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2015 | 1000 | 0.080 |
Why?
|
| Cryptococcosis | 1 | 2008 | 63 | 0.080 |
Why?
|
| Aged | 10 | 2019 | 70117 | 0.080 |
Why?
|
| Calcium | 3 | 2020 | 1537 | 0.080 |
Why?
|
| Gram-Negative Bacteria | 1 | 2007 | 100 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2009 | 702 | 0.070 |
Why?
|
| Caregivers | 1 | 2013 | 677 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 2483 | 0.070 |
Why?
|
| Gene Targeting | 1 | 2007 | 292 | 0.070 |
Why?
|
| Carcinoma, Papillary | 1 | 2010 | 584 | 0.070 |
Why?
|
| Macrophages | 1 | 2012 | 1304 | 0.070 |
Why?
|
| Shock, Septic | 1 | 2007 | 181 | 0.070 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2010 | 486 | 0.070 |
Why?
|
| Survival Rate | 3 | 2010 | 12221 | 0.070 |
Why?
|
| Pedigree | 2 | 2022 | 1890 | 0.070 |
Why?
|
| Prospective Studies | 6 | 2021 | 12873 | 0.070 |
Why?
|
| Genotype | 1 | 2013 | 4109 | 0.070 |
Why?
|
| Quality of Life | 1 | 2019 | 4532 | 0.060 |
Why?
|
| Expressed Sequence Tags | 1 | 2004 | 101 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2010 | 992 | 0.060 |
Why?
|
| North America | 1 | 2005 | 314 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2010 | 1819 | 0.060 |
Why?
|
| Base Sequence | 2 | 2014 | 4917 | 0.060 |
Why?
|
| Complement Activation | 1 | 2004 | 94 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 4320 | 0.060 |
Why?
|
| Linear Models | 2 | 2018 | 1085 | 0.060 |
Why?
|
| Reference Values | 1 | 2005 | 1099 | 0.060 |
Why?
|
| Peptides | 1 | 2009 | 1479 | 0.060 |
Why?
|
| Self Report | 2 | 2019 | 756 | 0.060 |
Why?
|
| Immune Sera | 1 | 2003 | 146 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 1547 | 0.060 |
Why?
|
| Leishmania tropica | 1 | 2002 | 1 | 0.060 |
Why?
|
| Prevalence | 1 | 2011 | 3260 | 0.060 |
Why?
|
| Leishmania major | 1 | 2002 | 21 | 0.050 |
Why?
|
| Leishmania donovani | 1 | 2002 | 13 | 0.050 |
Why?
|
| Homozygote | 2 | 2019 | 717 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 395 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 1037 | 0.050 |
Why?
|
| Urothelium | 1 | 2004 | 254 | 0.050 |
Why?
|
| Germany | 2 | 2014 | 111 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 1450 | 0.050 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2004 | 209 | 0.050 |
Why?
|
| Cell Movement | 1 | 2010 | 2466 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2014 | 4233 | 0.050 |
Why?
|
| Collagen Type IV | 1 | 2022 | 108 | 0.050 |
Why?
|
| CD40 Antigens | 1 | 2002 | 104 | 0.050 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2001 | 18 | 0.050 |
Why?
|
| Bacteremia | 1 | 2007 | 689 | 0.050 |
Why?
|
| Receptors, Formyl Peptide | 1 | 2001 | 11 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2001 | 37 | 0.050 |
Why?
|
| Pertussis Toxin | 1 | 2001 | 57 | 0.050 |
Why?
|
| Acute Disease | 3 | 2007 | 2422 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 14889 | 0.050 |
Why?
|
| Cell Division | 3 | 2003 | 2489 | 0.050 |
Why?
|
| Autoantigens | 1 | 2022 | 234 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2005 | 1681 | 0.050 |
Why?
|
| Interleukin-10 | 2 | 2002 | 478 | 0.050 |
Why?
|
| Endometrial Neoplasms | 1 | 2010 | 1341 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2001 | 284 | 0.050 |
Why?
|
| Chemokine CCL8 | 1 | 2000 | 2 | 0.050 |
Why?
|
| Chemokine CCL7 | 1 | 2000 | 12 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 4298 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2012 | 1538 | 0.050 |
Why?
|
| Rats, Transgenic | 1 | 2020 | 21 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 3154 | 0.050 |
Why?
|
| Caribbean Region | 1 | 2019 | 23 | 0.050 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2020 | 84 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 15694 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2005 | 2074 | 0.050 |
Why?
|
| United States | 3 | 2015 | 15433 | 0.040 |
Why?
|
| NFATC Transcription Factors | 1 | 2020 | 96 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2001 | 408 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2004 | 1818 | 0.040 |
Why?
|
| Age Factors | 3 | 2018 | 5377 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2015 | 5542 | 0.040 |
Why?
|
| Receptors, Interleukin-12 | 1 | 1999 | 12 | 0.040 |
Why?
|
| RNA Splice Sites | 1 | 2019 | 111 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 3203 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2020 | 142 | 0.040 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2019 | 168 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 3578 | 0.040 |
Why?
|
| Serum Albumin | 1 | 1999 | 257 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2019 | 161 | 0.040 |
Why?
|
| Calcium Channels | 1 | 2020 | 197 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2001 | 429 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2001 | 4053 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2014 | 1163 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2019 | 347 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 121 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2019 | 155 | 0.040 |
Why?
|
| Amino Acids | 1 | 2021 | 728 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2009 | 4078 | 0.040 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1998 | 157 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 2508 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2020 | 263 | 0.040 |
Why?
|
| Hemofiltration | 1 | 1998 | 20 | 0.040 |
Why?
|
| Phenotype | 2 | 2019 | 6295 | 0.040 |
Why?
|
| Sex Factors | 2 | 2018 | 2139 | 0.040 |
Why?
|
| CD3 Complex | 1 | 1999 | 314 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 1999 | 271 | 0.040 |
Why?
|
| Rehabilitation | 1 | 2018 | 46 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2010 | 15862 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2022 | 779 | 0.040 |
Why?
|
| Th2 Cells | 1 | 1999 | 257 | 0.040 |
Why?
|
| Th1 Cells | 1 | 1999 | 250 | 0.040 |
Why?
|
| Immune System Diseases | 1 | 2018 | 65 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 344 | 0.040 |
Why?
|
| Carboplatin | 2 | 2010 | 823 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 4844 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 4971 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2016 | 43 | 0.040 |
Why?
|
| Conservative Treatment | 1 | 2017 | 58 | 0.040 |
Why?
|
| PAX2 Transcription Factor | 1 | 2016 | 43 | 0.040 |
Why?
|
| Osmolar Concentration | 1 | 2016 | 204 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 8865 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 1999 | 558 | 0.040 |
Why?
|
| Chlorides | 1 | 2016 | 139 | 0.040 |
Why?
|
| beta 2-Microglobulin | 1 | 2016 | 184 | 0.040 |
Why?
|
| Brain Edema | 1 | 2016 | 86 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2008 | 3869 | 0.040 |
Why?
|
| Apoptosis | 2 | 2008 | 7591 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1998 | 1062 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 192 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 714 | 0.030 |
Why?
|
| Exons | 1 | 2019 | 1328 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2016 | 182 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 7789 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 403 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2020 | 1113 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2017 | 371 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2019 | 444 | 0.030 |
Why?
|
| Sodium | 1 | 2016 | 353 | 0.030 |
Why?
|
| Arthritis | 1 | 2016 | 139 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 1999 | 657 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 672 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2018 | 270 | 0.030 |
Why?
|
| France | 1 | 2015 | 108 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 13658 | 0.030 |
Why?
|
| Brazil | 1 | 2015 | 165 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 2195 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 10001 | 0.030 |
Why?
|
| Antibodies | 1 | 2018 | 838 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2014 | 354 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1945 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2013 | 31 | 0.030 |
Why?
|
| Cetuximab | 1 | 2014 | 472 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 1863 | 0.030 |
Why?
|
| Stents | 1 | 2019 | 1096 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2014 | 997 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2020 | 1589 | 0.030 |
Why?
|
| International Cooperation | 1 | 2013 | 323 | 0.030 |
Why?
|
| Benchmarking | 1 | 2014 | 273 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 1021 | 0.030 |
Why?
|
| Mastectomy | 1 | 2018 | 1534 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 1382 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 14289 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 313 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2009 | 2314 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 401 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 1052 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2010 | 10331 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 4938 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 1178 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 2738 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 1544 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 1265 | 0.020 |
Why?
|
| ras Proteins | 1 | 2014 | 770 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2010 | 4988 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2009 | 29 | 0.020 |
Why?
|
| Heart Rate | 1 | 2013 | 737 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2009 | 43 | 0.020 |
Why?
|
| Toxoplasmosis | 1 | 2009 | 28 | 0.020 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2009 | 53 | 0.020 |
Why?
|
| Microvessels | 1 | 2010 | 135 | 0.020 |
Why?
|
| Anemia | 1 | 2014 | 689 | 0.020 |
Why?
|
| Hospitalization | 1 | 2018 | 2083 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2016 | 1664 | 0.020 |
Why?
|
| Cryptococcus neoformans | 1 | 2008 | 27 | 0.020 |
Why?
|
| Antigens, Fungal | 1 | 2008 | 40 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2014 | 1987 | 0.020 |
Why?
|
| Histamine Antagonists | 1 | 2007 | 17 | 0.020 |
Why?
|
| Rats, Inbred WKY | 1 | 2008 | 110 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 604 | 0.020 |
Why?
|
| Animal Feed | 1 | 2008 | 81 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2007 | 3033 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1331 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1165 | 0.020 |
Why?
|
| Macrophages, Peritoneal | 1 | 2007 | 66 | 0.020 |
Why?
|
| Breast | 1 | 2014 | 1344 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2008 | 133 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 665 | 0.020 |
Why?
|
| Spleen | 1 | 2009 | 676 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 2522 | 0.020 |
Why?
|
| Platelet Count | 1 | 2007 | 490 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 717 | 0.020 |
Why?
|
| Carotid Artery Diseases | 1 | 2008 | 196 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2013 | 806 | 0.020 |
Why?
|
| Mast Cells | 1 | 2007 | 223 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 2488 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 6100 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 2291 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2008 | 292 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 2203 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 3343 | 0.020 |
Why?
|
| Family Practice | 1 | 2005 | 125 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2005 | 109 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2007 | 538 | 0.020 |
Why?
|
| Depression | 1 | 2015 | 1715 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 690 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 2403 | 0.010 |
Why?
|
| Coronary Disease | 1 | 2008 | 764 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2007 | 677 | 0.010 |
Why?
|
| Mice, Congenic | 1 | 2003 | 30 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2014 | 2967 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2003 | 182 | 0.010 |
Why?
|
| Endotoxins | 1 | 2003 | 96 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2003 | 355 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2010 | 1248 | 0.010 |
Why?
|
| Sheep | 1 | 2003 | 258 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 334 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2003 | 295 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2003 | 521 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2003 | 266 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 3890 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 2594 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2008 | 1129 | 0.010 |
Why?
|
| Life Style | 1 | 2005 | 612 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 1586 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 699 | 0.010 |
Why?
|
| Weight Loss | 1 | 2005 | 627 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 7702 | 0.010 |
Why?
|
| Kidney Tubules, Distal | 1 | 2000 | 22 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2000 | 189 | 0.010 |
Why?
|
| U937 Cells | 1 | 2000 | 171 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 10035 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2000 | 236 | 0.010 |
Why?
|
| Growth Substances | 1 | 2000 | 300 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2003 | 1869 | 0.010 |
Why?
|
| Ureter | 1 | 2000 | 209 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2000 | 771 | 0.010 |
Why?
|
| Exercise | 1 | 2005 | 1183 | 0.010 |
Why?
|
| Diet | 1 | 2005 | 1440 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 7226 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 1489 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2002 | 1130 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 5114 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 3639 | 0.010 |
Why?
|